Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grove SHOC2 disruptor
- Development stage
- Preclinical
- Lead developer
- Grove Biopharma
- Modality
- Small Molecules
01
Overview
The Grove SHOC2 disruptor is a preclinical small-molecule therapeutic candidate being developed by Grove Biopharma. It is designed to disrupt the SHOC2-MRAS-PP1C protein complex, which serves as a crucial scaffold in the RAS/MAPK signaling pathway. By preventing the formation or stability of this complex, the drug inhibits the activation of RAF by RAS, thereby suppressing oncogenic signaling in RAS-mutant cancers. The primary indications for this program include non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. While Grove Biopharma's broader platform focuses on 'Bionic Biologics' or precision-linked proteomimetics (protein-like polymers), this specific candidate is identified in company pipelines as a small-molecule disruptor.
- Other names
- SHOC2-MRAS-PP1C disruptorSHOC-2-MRAS-PP1C disruptorSHOC 2-MRAS-PP1C disruptorGroove SHOC2 disruptor
02
Targets
SHOC2 (Leucine-rich repeat protein SHOC-2)NRAS (Neuroblastoma RAS viral oncogene homolog)
Beyond the preview
Go deeper on Grove SHOC2 disruptor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grove SHOC2 disruptor.